(Q46001028)

18 December 2017

title

Pharmacological dose of vitamin B12 is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients. (English)

1 reference

18 December 2017

0 references

0 references

1 reference

Yi-Wen Chiu

1

1 reference

18 December 2017

Jer-Ming Chang

2

1 reference

18 December 2017

Shang-Jyh Hwang

3

1 reference

18 December 2017

Jer-Chia Tsai

4

1 reference

18 December 2017

Hung-Chun Chen

5

1 reference

18 December 2017

publication date

1 January 2009

1 reference

18 December 2017

published in

Renal Failure

1 reference

18 December 2017

volume

31

1 reference

18 December 2017

issue

4

1 reference

18 December 2017

page(s)

278-283

1 reference

18 December 2017

Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

The effect of two different doses comprising the simultaneous administration of intravenous B-complex vitamins and oral folic acid on serum homocysteine levels in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

It is important to lower homocysteine in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

Effect of Usual Doses of Folate Supplementation on Elevated Plasma Homocyst(e)ine in Hemodialysis Patients: No Difference between 1 and 5 mg Daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08860220902780010

10.1080/08860220902780010

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017